Patients undergoing autologous peripheral blood stem cell transplantation (PBSC) frequently require the sequential insertion of two central venous catheters, one for leukapheresis and one for transplant support. Hybrid catheters suitable for leukapheresis and longterm use have been increasingly used, but there is limited information regarding their performance and complication rate. The purpose of this study was to determine the performance of the Pheres-Flow hybrid catheter when utilized for both leukapheresis and transplant support, with particular emphasis on the incidence of infectious and occlusive complications. We prospectively analyzed the performance of 92 catheters in 82 consecutive patients who underwent autologous peripheral blood stem cell (PBSC) transplantation. Occlusion was the most frequent complication of this catheter with 29% of the patients experiencing difficulty drawing blood or infusing fluids. Infection was another frequent complication. Twenty-two percent of patients developed catheter-related bloodstream infections and 15 catheters had to be removed because of proven or suspected infection that did not respond to antibiotic therapy. Nevertheless, 77% of patients were able to complete leukapheresis and transplant support with only one catheter. We conclude that the utilization of the Pheres-Flow catheter for both leukapheresis and transplant support is feasible, but that new strategies need to be developed to decrease the incidence of occlusive and infectious complications of hybrid catheters.
Vascular access is a critical aspect in the management of patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation. The need to procure reliable access for leukapheresis and transplant support frequently requires the sequential insertion and use of two central venous catheters. The first catheter is usually a short-term, non-tunneled, large bore, stiff central venous catheter that allows the continuous high flow rate necessary for leukapheresis. The second catheter is usually a silastic long-term, tunneled catheter utilized for the administration of chemotherapy, infusion of large volumes of fluids and blood transfusions necessary for transplant support.
In recent years, silastic tunneled catheters that allow the continuous high flow rates necessary for leukapheresis and that are also suitable for long-term use have been developed. These catheters, also referred to as 'hybrid catheters', are increasingly being used for both peripheral blood stem cell (PBSC) harvest and transplant support. The use of a hybrid catheter circumvents the need to insert two different catheters, one for leukapheresis and another for vascular access support during the transplant period. There is limited information regarding the performance of hybrid catheters utilized for PBSC transplantation. [1] [2] [3] The purpose of this study was to determine the performance of the Pheres-Flow hybrid catheter during autologous PBSC harvest and transplantation with particular emphasis on the incidence of catheter-related bloodstream infection (CR-BSI) and occlusive complications. We report our experience with this hybrid catheter when utilized for autologous PBSC harvest and transplant support.
Patients and methods

Catheter description, insertion and maintenance
The Pheres-Flow, formerly known as the Neostar (Horizon Medical Products, Manchester, GA, USA), is a central venous triple-lumen silicone catheter with intraluminal diameters of 1.5 mm (blue port), 1.9 mm (red port), and 1.1 mm (white port). The overall diameter is 4.2 mm. The length of the catheter from tip to cuff is 30 cm, and it can be trimmed as needed at the time of insertion. This catheter delivers the adequate flow rates necessary for leukapheresis and is also suitable for blood sampling, administration of chemotherapy, infusion of large volumes of fluids, total parenteral nutrition and blood transfusions.
All Pheres-Flow catheters were inserted by one of four interventional radiologists, all faculty members of the University of Texas Health Science Center at San Antonio. All catheters were inserted in the angiography suite. The right internal jugular vein was the preferred access site, as it forms a straight line with the brachiocephalic vein and superior vena cava. However, if this vein was occluded or could not be accessed, the left internal jugular vein was then used. Under sterile conditions, the internal jugular vein was accessed under ultrasound and fluoroscopic guidance and a guide wire was introduced. Fascial dilators were then inserted sequentially over the guide wire to allow placement of the peel-away catheter-introduction sheath into the internal jugular vein. A tunnel was then created by making a distal incision into the subcutaneous tissues from the region of the infraclavicular fossa to the internal jugular venous puncture at the neck. This was done using blunt dissection with a tunneler device, which carried the catheter mounted over its proximal end. Upon completion of the tunnel, the catheter was pulled to its subcutaneous position. Catheters were tunneled subcutaneously with the Dacron cuff positioned in the proximal third of the tunnel. Proper catheter length was then determined by placing a guide wire to the superior cavoatrial junction and marking the wire at the level of the skin. The distal end of the catheter was then cut to length. The fascial dilator was removed over the guide wire and the peel-away sheath was inserted into the superior vena cava. The distal end of the catheter was then introduced through the sheath to the cavoatrial junction and the sheath was peeled away. The small neck incision was sutured and sterile tape was applied to the wound. A sterile dressing was placed. The final location of the tip was the superior vena cava-right atrium junction. The location of the catheter tip was confirmed by fluoroscopy. Prophylactic antibiotics were not routinely given at the time of insertion.
After line placement, a nurse assessed the catheter at least twice a week in the outpatient setting and daily in the inpatient setting. The nurse documented the appearance of the line site and any difficulties withdrawing blood or infusing fluids on a flow sheet specifically designed for this study. During dressing changes, the catheter exit site was cleaned with 70% isopropyl alcohol swabs (Aplicare, Brandford, CT, USA); a Biopatch (2.5 cm antimicrobial dressing with chlorhexidine gluconate, Johnson & Johnson, Arlington, TX, USA) placed at the exit site and a clean occlusive dressing applied. Dressing changes were performed at least every 5 days, or more frequently if necessary, using a sterile technique. As an inpatient, each lumen was flushed daily with normal saline followed by 1 ml of sodium heparin 100 U/ml (Elkins-Sinn, Cherry Hill, NJ, USA). To maintain catheter patency between outpatient treatments, each lumen was flushed with normal saline followed by 1 cc of sodium heparin 1000 U/ml, at least weekly in the outpatient setting. Oral anticoagulants were not given.
It was our intention to remove the catheter after all posttransplant support, including blood transfusions and electrolyte replacement, was completed. A minimum platelet count of 50 ϫ 10 9 /l was required at the time of catheter removal. The interventional radiologists in the angiography suite removed the catheter. Some patients had their catheter removed before completion of the post-transplant support period. Reasons for premature catheter removal included exit site infection, persistent bacteremia despite adequate antibiotic therapy or subcutaneous tunnel infection. The attending transplant physician, in consultation with the interventional radiologist, made the decision regarding catheter removal or change depending on the clinical situation. Personnel evaluating the catheter performance did not influence the decision to remove or change the catheter at any time.
Prophylactic therapy and management of neutropenic fever
All patients received prophylactic therapy with ciprofloxacin during the neutropenic period. Oral ciprofloxacin was started when the absolute neutrophil count (ANC) was less than 1 ϫ 10 9 /l. Ciprofloxacin was discontinued when the patient became febrile and required empiric, intravenous, broad spectrum antibiotic therapy or when the absolute neutrophil count exceeded 1 ϫ 10 9 /l. Patients also received prophylactic therapy for Pneumocystis carinii with trimethoprim/sulfamethoxazole.
Trimethoprim/sulfamethoxazole was given during the conditioning regimen, and was discontinued 24 h before the transplant to avoid engraftment delay. Prophylaxis with trimethoprim/sulfamethoxazole was resumed when the ANC reached 0.5 ϫ 10 9 /l for 2 consecutive days or 30 days after the transplant, whichever occurred first, and was continued until 90 days post-transplant. Patients who were serologically positive for herpes simplex received prophylaxis with acyclovir. Oral acyclovir was started at the onset of conditioning therapy. Acyclovir was continued until 30 days after the transplant. Fluconazole was used routinely as prophylaxis for fungal infections. Fluconazole was initiated once the ANC was below 1 ϫ 10 9 /l and continued until the ANC was equal or higher than 1 ϫ 10 9 /l. Fluconazole was also discontinued if the patient required treatment with Amphotericin B or any other systemic antifungal agent. If the patient was unable to tolerate oral medications, prophylactic medications were given intravenously.
All patients received the recombinant hematopoietic growth factor sargramostim (GM-CSF, Leukine; Immunex, Seattle, WA, USA) or filgrastim (G-CSF, Neupogen, Amgen, Thousand Oaks, CA, USA) from the day of transplantation until WBC of 5 ϫ 10 9 /l or a WBC of 2 ϫ 10 9 /l was recorded for 2 consecutive days.
Intravenous antibiotic therapy was initiated when patients developed a temperature of 100.5°F (37.8°C) or higher. Before starting intravenous antibiotics, blood from both the central venous catheter and peripheral blood were sent for culture. Urine analysis, urine culture and chest Xray were also obtained during the first febrile episode. Anti-biotic therapy was given following institutional clinical practice guidelines. Typically, this included an intravenous third or fourth generation antipseudomonal cephalosporin or beta-lactam/lactamase inhibitor antibiotic given as initial empiric therapy. Patients in whom a central venous catheter infection was suspected also received vancomycin as part of their initial therapy. Patients were cultured every 24 h while they remained febrile unless the fever was temporally related to blood transfusion or hematopoietic stem cell growth factor administration. Vancomycin was added to the antibiotic therapy of patients who remained febrile for 48 h after initiation of cephalosporin or beta lactam/lactamase inhibitor antibiotic therapy. The antibiotic therapy was modified as blood culture results and organism sensitivity became available.
Clinical and catheter-related parameters analyzed
We prospectively analyzed the performance of the PheresFlow during PBSC harvest and transplant support. All patients who underwent PBSC harvest and autologous transplantation at the Audie L Murphy Memorial Veterans Hospital and the University of Texas Health Science Center at San Antonio, Texas, from January 1999 to June 2001 were analyzed. A flow sheet designed specifically for this study was filled out on a daily basis. Another form designed for this study was filled out by the interventional radiologist at the time of catheter insertion documenting the site of insertion and any difficulty or complications experienced during insertion of the catheter.
Clinical information recorded included the patient's age, sex, diagnosis, PBSC mobilization regimen, and number of leukapheresis procedures required for harvesting PBSC. In addition, chemotherapy agents and hematopoietic growth factor given for mobilization, as well as the pre-transplant conditioning regimen were recorded and analyzed.
Catheter-related information obtained included previous history of catheter problems, such as infection and occlusion, date and site of Pheres-Flow catheter insertion and complications during catheter insertion. The presence of catheter occlusion and any therapy given for this complication during leukapheresis and transplant period were recorded. Occlusion of the vascular access device was defined as difficulty or inability to withdraw blood from any of the ports. Difficulty infusing fluids or flushing any of the ports was also considered a sign of occlusion. Catheter tip ultrasounds or venograms were not done routinely to evaluate catheter occlusion.
Infections involving the catheter exit site were recorded. The catheter exit site was considered infected if patients developed erythema, tenderness, induration or discharge at the catheter exit site. The presence and duration of fever while the catheter was in situ were recorded. Results of blood cultures obtained from the central venous catheter and from venipuncture of peripheral veins were recorded and analyzed. The definition of catheter-related blood stream infections as defined by the Centers for Disease Control and Prevention (CDC), was utilized. 4, 5 Catheterrelated bloodstream infection (CR-BSI) was defined as isolation of the same organism (identical species and antibiogram) from a culture of a catheter segment and/or Bone Marrow Transplantation from the peripheral blood of a patient with accompanying clinical symptoms of bloodstream infection with no other apparent source of infection. The records of all patients who had positive blood cultures were reviewed by an independent infectious disease specialist who determined if the patient met the definition of CR-BSI, based on the clinical picture and laboratory findings.
The reason for catheter removal and the need to insert another vascular access device to complete the planned therapy was recorded.
Results
Patient characteristics
We prospectively analyzed the performance of 92 PheresFlow catheters in 82 consecutive patients who underwent high-dose chemotherapy and PBSC transplantation. The median age of patients was 55 years (range 22-74) and 77 patients (94%) were men. The most common indications for transplantation were multiple myeloma (37 patients) and lymphoma (35 patients) ( Table 1 ). Hematopoietic stem cell mobilization regimens included G-CSF alone in 37 patients (45%), paclitaxel and G-CSF in 27 patients (33%) and cyclophosphamide in combination with G-or GM-CSF in 17 patients (21%). One patient received GM-CSF for mobilization of hematopoietic stem cells. Pre-transplant conditioning regimens included melphalan in 34 patients (41%), the combination of cyclophosphamide, etoposide and carmustine (BCNU) in 30 patients (36%) and cyclophosphamide in combination with thiothepa in four patients (5%). Three patients received busulfan and melphalan and three patients received the combination of BCNU, etoposide, cytarabine and melphalan as conditioning regimens. Eight patients (10%) were treated with other conditioning regimens (Table 1) . Only two patients received total body irradiation as part of their conditioning regimen: one in combination with cyclophosphamide and the other one in combination with cyclophosphamide and etoposide.
Twenty-three patients (28%) reported catheter complications with previous vascular access devices. Of those 23 patients, 14 had a history of infection, eight had a history of catheter occlusion, and one patient developed bleeding during placement of a vascular access device.
The median white blood cell count (WBC) at the time of the insertion was 7000/l (range 1600 to 52 800) and the median platelet count at the time of insertion was 206 000/l (range 17 000 to 514 000). The median duration of neutropenia was 8 days (range 3-12).
All catheters were inserted into the internal jugular vein. There was no pneumothorax, bleeding or any complication during catheter insertion. The median duration of catheter insertion was 32 days (range 12-109). The median number of phereses performed per patient was two (range 1-11). The median number of days from harvest to transplant was 14 (range 3-77). The median number of days from transplant to catheter removal was 15 (range 0-37).
Fever and infectious complications
Seventy-two of the 82 patients (88%) had fever while the catheter was in situ during the stem cell mobilization/ leukapheresis phase or during the post-transplant neutropenic period (Table 2) . Fifty-nine of the 72 patients who developed fever (82%) became febrile during the post-conditioning regimen neutropenic period. Thirteen patients developed fever before infusion of the stem cells: seven during the conditioning regimen, two while undergoing leukapheresis, and five patients who required more than one mobilization regimen to harvest stem cells developed fever between mobilization regimens.
Eighteen of the 82 patients (22%) met the CDC criteria for CR-BSI and were treated with appropriate antibiotics based on sensitivity (Table 3) . Three patients had bacteremia prior to the day of transplant, and 15 had bacteremia Table 2 Catheter-related parameters and complications observed in 82 patients who utilized the Pheres-Flow hybrid catheter for PBSC harvest and transplant support Complications related to insertion, n 0 Fever, n (%) 72 (88) Catheter occlusion, n (%) 24 (29) Patients with CR-BSI, n (%) 18 (22) (Table 4 ). The catheter was removed in seven patients due to catheter exit site infection or persistent bacteremia despite adequate antibiotic therapy. In eight patients, the catheter was removed because of persistent fever without clinical evidence of catheter infection or CR-BSI at the time of the catheter removal. In four of these patients, CR-BSI or other evidence of infection became evident after removing the catheter.
Of the 14 patients with a previous history of catheter infections, only two developed CR-BSI. Therefore, there was no relationship between a history of previous catheter infection and the development of CR-BSI during the leukapheresis or transplant period. Only four of the 18 patients that developed CR-BSI experienced occlusion of the hybrid catheter suggesting that there was no relationship between catheter occlusion and infection in these patients.
Occlusive complications
Twenty-four of the 82 patients (29%) experienced occlusive complications defined as difficulty infusing fluids or withdrawing blood from their catheter ( Table 2 ). Change in the patient's position reproducibly allowed the withdrawal of blood and infusion of fluid in two patients. The other 22 patients required infusions of thrombolytic agents such as urokinase or tissue plasminogen activator (t-PA). No catheter had to be removed due to occlusion.
Reasons for removal of hybrid catheter
Sixty-two patients, or 76%, completed PBSC harvest and transplant support with one hybrid catheter as planned, and their catheters were removed after completion of treatment (Table 4) . Two patients died with the catheter in place. Two catheters were accidentally pulled out by the patients, and one catheter was removed because of a tear in one of the lines. Only 11 patients (13%) required insertion of another central venous catheter to complete treatment related to their transplant.
Discussion
During the last few years, silastic long-term tunneled catheters with the capacity to deliver the flow rates necessary for leukapheresis have been developed that have made it possible to use one catheter, instead of two, for leukapheresis and transplant support. However, there is limited information regarding the performance of hybrid catheters and their complications. We elected to prospectively analyze the performance of the Pheres-Flow hybrid catheter for leukapheresis and transplant support. We analyzed the performance and complications of 92 catheters in 82 patients who underwent leukapheresis and transplant support with this hybrid catheter.
There were no complications related to insertion of the Pheres-Flow catheter during the study period including pneumothorax or bleeding. The fact that these catheters were inserted by experienced interventional radiologists under sonographic and fluoroscopic visualization probably contributed to the absence of complications. The complication rate related to insertion of hybrid catheters has been reported to be between 0 and 3.5%, suggesting that the risk of complications during insertion of these catheters is low. [1] [2] [3] Infection is one of the most frequent complications of central venous catheters. [6] [7] [8] We found an incidence of CR-BSI as defined by the CDC of 22%. The hybrid catheter had to be removed prematurely in 15 patients due to infection or persistent fever. Twelve of these patients had evidence of exit site infection or CR-BSI. In our study the majority of the CR-BSI (nine of 22) were due to Staphylococcus coagulase negative. Nevertheless, almost one quarter of the CR-BSI in our series was due to Pseudomonas aeruginosa and one patient died of Pseudomonas aeruginosa sepsis. It is of interest that we saw three episodes of CR-BSI with Enterococcus faecium, probably a reflection of the increased frequency of infection seen with this organism in oncology patients in the United States. 9 In our experience, 83% of the patients who developed CR-BSI developed the bacteremia during the post-transplant neutropenic period. The rest of the patients developed CR-BSI during the mobilization/leukapheresis phase or during administration of the conditioning regimen.
Of the 14 patients with a previous history of catheter infections, only two developed CR-BSI during the mobilization or transplant period. Therefore, there was no relationship between a history of previous catheter infection and the development of sepsis or catheter-related infection during the leukapheresis or transplant period.
Lazarus and collaborators 1 reported their experience with two different hybrid catheters, the Quinton-Raaf PermCath (first described as the Quinton HemoCath) and the BardHickman catheter. These investigators reported on 112 consecutive patients who underwent autologous PBSC collecBone Marrow Transplantation tion and transplantation using one of these two central venous catheters. They reported 17 episodes of bacteremia (15%) and two exit site infections in patients who utilized the Quinton-Raaf PermCath or the Bard-Hickman hybrid catheters for pheresis and transplant support. In their experience, only two patients experienced premature removal of their catheters due to infection. Forty percent of the bacteremias reported in their study were due to Staphylococcus epidermidis. Similar to our experience, most of the bacteremias (88%) were observed during the posttransplant neutropenic period.
Meisenberg and collaborators 2 also reported their experience with Quinton-Raaf and Bard-Hickman catheters for pheresis and transplant support. They reported 22 episodes of infection in patients who utilized the Quinton-Raaf PermCath or the Bard-Hickman hybrid catheters for pheresis and transplant support. Half of these infections were reported as early infections, defined as infection diagnosed within 2 weeks of placement of the catheter. Nine of the 11 were exit site or tunnel infections and only two involved bacteremia (both S. aureus). The authors attributed five of these infections to operative technique because the infection developed within 48 h of catheter placement. They also reported another 11 episodes of late infection defined as infection diagnosed after 2 weeks of insertion. Seven of these infections were due to gram-positive bacteria. In total, they reported an incidence of bacteremia of 8%. They reported that five catheters were prematurely removed due to infection and four other catheters were removed for persistent fever without documented infection.
In a preliminary report, Cera and collaborators 3 analyzed a group of patients who utilized the Pheres-Flow catheter for PBSC harvest and autologous transplantation. They reported that nine of 90 or 11% developed bacteremia. Nevertheless, another 11 catheters were prematurely removed because of persistent fever, although they were not able to document any infection. No information was given regarding the type of organisms responsible for the bacteremias or infection.
The frequency of bacteremia in the few reported studies of hybrid catheters utilized for both PBSC harvest and autologous transplant, including this study, range from 8% to 22% (Table 5 ). Despite the fact that hybrid catheters were utilized for both leukapheresis and transplant support, the frequency of bacteremia observed in these studies is similar to the frequency of bacteremia described in previous studies of central venous catheters in patients undergoing pheresis or autologous transplantation. [10] [11] [12] Differences in the observed frequency of bacteremias among the studies utilizing hybrid catheters for pheresis and transplant support could have several explanations. The fact that our study was prospective makes it more likely Table 4 Reason for catheter removal (n = 82)
Completion of therapy, n (%) 62 (77) Proven or suspected infection, n (%) 15 (18) Died with catheter in place, n (%) 2 (2) Accidentally pulled out, n (%) 2 (2) Tear in port, n (%) 1 (1) that complications, including bacteremia will be detected, in comparison to retrospective analyses. Differences in catheter design could also be responsible for the difference in frequency of bacteremia. Both Lazarus and Meisenberg's reports describe the experience with two hybrid catheters, the Quinton-Raaf PermCath and the Bard-Hickman multipurpose catheters. Both catheters are dual-lumen, in contrast to the Pheres-Flow, which is a triple-lumen catheter.
The fact that the Pheres-Flow is a triple-lumen catheter could contribute to the increased incidence of CR-BSI observed in our study when compared with the doublelumen Quinton-Raaf PermCath and the Bard-Hickman multipurpose catheter, since it has been reported that the incidence of infection increases with the number of catheter lumens. 13 Nevertheless, the frequency of bacteremia in Meisenberg's study was lower than in the study reported by Lazarus. It has to be noted that although both reports utilized two different catheters, they reported their experience globally, which makes it difficult to determine if there was any difference in the complication rate between catheters. Prospective, randomized trials comparing the performance of different hybrid catheters will be necessary to determine if there are differences in the incidence of infections and other complications between hybrid catheters.
Occlusion remains a frequent complication of vascular access devices. 14, 15 Occlusions of vascular access devices frequently delay planned treatment and require the infusion of expensive thrombolytic agents to lyse clots occluding the lumen or tip of the catheter. In our experience, 29% of the hybrid catheters utilized developed an occlusion during the period of insertion. The incidence of occlusion in our study is similar to that reported by Lazarus and collaborators utilizing the Quinton-Raaf PermCath and Bard-Hickman hybrid catheters, and of Cera and collaborators' report utilizing the Pheres-Flow hybrid catheter. 1, 3 Nevertheless, it has to be noted that the median duration of insertion in the Lazarus report was 63 days compared to our median duration of insertion of only 32 days. In contrast to the Lazarus experience, no catheter in our report had to be removed prematurely due to occlusion. The occlusion rate in Meisenberg's report was only 5%, which is significantly lower than previously reported. 5 The reason for the lower incidence of occlusion in this report could not be determined, although it is of interest that warfarin was used during the transplant support phase as long as the platelet count was over 40 ϫ 10 9 . It was our intention to utilize only one hybrid catheter for the leukapheresis procedure, the administration of the conditioning regimen and transplant support. In most cases, the catheter was inserted 1 or 2 days before PBSC harvest. It was our experience that this approach is feasible and that most patients are able to undergo PBSC harvest and transplantation with only one hybrid catheter. In our experience 77% of patients completed their harvest and transplant support with only one hybrid catheter (Table 4) . Catheters had to be removed prematurely because of infection in 18% of our patients. Two percent of the catheters were accidentally pulled out by the patients, two patients died with the catheter in place and one catheter had to be removed because of a tear in one of the ports. Of particular importance was the fact that only 11 patients (13%) required insertion of another central venous catheter to complete the planned treatment. The remaining patients, in whom the catheter was removed before completion of the planned therapy, were able to receive their treatment through peripheral veins without the need to insert any other vascular access device. In the report by Lazarus, only 17 of 112 catheters (15%) were removed before completion of therapy. 1 Of interest is the fact that most of the catheters removed in their experience were removed for persistent thrombus or mechanical problems, while most of the catheters removed in our series were removed because of infectious complications. In Meisenberg's report, 16% of catheters had to be removed before completion of the planned therapy. 2 In their experience, 63% of catheters had to be removed because of mechanical problems, mostly catheter malposition. Other causes for premature removal included infection, fever without documented infection and occlusion of the catheter.
In summary, we conclude that the utilization of the Pheres-Flow hybrid catheter for leukapheresis and transplant support is feasible, since 77% of patients completed their planned therapy with one catheter. Occlusion was the most frequent complication of this hybrid catheter, with 29% of patients experiencing difficulty drawing blood or infusing fluids. Infection was a frequent complication of this catheter. Utilizing the strict criteria of the CDC, 22% of patients developed CR-BSI. New strategies need to be developed to decrease the incidence of occlusive and infectious complications seen with hybrid vascular access devices.
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